GlassScriptPhysician profile
Sarah Kung
NPI 1891182010
$984.78
in general payments reported to CMS, 2019-2025
21 companies · $485 in 2025
The $485 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2023: $207 · 2024: $179 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $146.55 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.48 | 2022-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $125.36 | 2022-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $115.90 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $66.21 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $59.14 | 2022-2025 | Airsupra, Tezspire |
| Novo Nordisk INC | $47.71 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Mylan Specialty L.P. | $39.79 | 2022-2023 | Yupelri |
| Verona Pharma, INC. | $31.47 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $24.07 | 2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $24.05 | 2023 | Glassia |
| Baxter Healthcare | $23.69 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $20.91 | 2025 | Brinsupri, Arikayce |
| Amgen INC. | $19.62 | 2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $18.95 | 2023 | Austedo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $18.64 | 2023 | Tymlos |
| Electromed, INC. | $17.32 | 2024 | Smartvest |
| Merck Sharp & Dohme LLC | $16.38 | 2025 | Zerbaxa |
| Philips North America LLC | $14.61 | 2025 | Vest Therapy Und |
| Alexion Pharmaceuticals, INC. | $14.60 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Kung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.